Distribution of peroxisome proliferator-activated receptor-gamma polymorphisms in Chinese and Dutch patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 16, Issue 2, 2010, Pages 312-319

  Shrestha, Umid Kumar ^a   Karimi, Ouafae ^b   Crusius, J Bart A ^b   Zhou, Feng ^c   Wang, Zhongli ^d   Chen, Zhitao ^a   Van Bodegraven, A A ^b   Xiao, Jun ^a   Morré, Servaas A ^b   Wang, Hongling ^a   Li, Jin ^c   Xia, Bing ^a,b,d  

^a WUHAN UNIVERSITY   (China)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Clinical Research Center for Intestinal and Colorectal Diseases of Hubei Province   (China)

^d Hubei Province Key Laboratory of Allergy and Immunology   (China)

Author keywords

C161T; Peroxisome proliferator activated receptor gamma; Polymorphism; Pro12Ala; Ulcerative colitis

Indexed keywords

ALANINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROLINE;

ADULT; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DNA POLYMORPHISM; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; ULCERATIVE COLITIS;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; COLITIS, ULCERATIVE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; NETHERLANDS; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA;

EID: 73949104165     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21059     Document Type: Article

References (45)

1. Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007;369:1627-1640.
2. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology. 2001;120:622-635.
3. Dubuquoy L, Rousseaux C, Thuru X, et al. PPAR γ as a new therapeutic target in inflammatory bowel diseases. Gut. 2006;55:1341-1349.
4. Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest. 1999;104:383-389.
5. Martin G, Schoonjans K, Staels B, et al. PPARγ activators improve glucose homeostasis by stimulating fatty acid uptake in the adipocytes. Atherosclerosis. 1998;137(suppl):S75-S80.
6. Brun RP, Tontonoz P, Forman BM, et al. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 1996;10:974-984.
7. Schoonjans K, Martin G, Staels B, et al. Peroxisome peroliferator- activated receptors, orphans with ligands and functions. Curr Opin Lipidol. 1997;8:159-166.
8. Beamer BA, Negri C, Yen CJ, et al. Chromosomal localization and partial genomic structure of the human peroxisome proliferator activated receptor-gamma (hPPAR gamma) gene. Biochem Biophys Res Commun. 1997;233:756-759.
9. Tontonoz P, Hu E, Graves RA, et al. mPPAR gamma2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 1994;8:1224-1234.
10. Fajas L, Auboeuf D, Raspe E, et al. The organization, promoter analysis, and expression of the human PPAR gamma gene. J Biol Chem. 1997;272:18779-18789.
11. Zhu Y, Qi C, Korenberg JR, et al. Structural organization of mouse peroxisome proliferator-activated receptor gamma (mPPAR gamma) gene: alternative promoter use and different splicing yield two mPPAR gamma isoforms. Proc Natl Acad Sci U S A. 1995;92:7921-7925.
12. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell. 1994;79:1147-1156.
13. Shah YM, Morimura K, and Gonzalez FJ. Expression of peroxisome proliferator-activated receptor-c in macrophage suppresses experimentally induced colitis. Am J Physiol Gastrointest Liver Physiol. 2007;292:G657-G666.
14. Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator- activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270: 12953-12956.
15. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med. 1998;4:1053-1057.
16. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPAR gamma enhance colon polyp formation. Nat Med. 1998;4:1058-1061.
17. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPAR gamma. Nat Med. 1998;4:1046-1052.
18. Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun. 1997;241:270-274.
19. Deeb SS, Fajas L, Nemoto M, et al. A Pro12Ala substitution in PPARc2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998;20:284-287.
20. Masugi J, Tamori Y, Mori H, et al. Inhibitory effect of a proline-to alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione induced adipogenesis. Biochem Biophys Res Commun. 2000;268:178-182.
21. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26:76-80.
22. Herrmann SM, Ringel J, Wang JG, et al. Peroxisome proliferator-activated receptor-gamma 2 polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes: the Berlin Diabetes Mellitus (BeDiaM) Study. Diabetes. 2002;51:2653-2657.
23. Landi S, Moreno V, Gioia-Patricola L, et al. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 2003;63:3560-3566.
24. Murtaugh MA, Ma KN, Caan BJ, et al. Interactions of peroxisome proliferator-activated receptor γ and diet in etiology of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:1224-1229.
25. Koh WP, Yuan JM, Van Den Berg D, et al. Peroxisome proliferator-activated receptor (PPAR) γ gene polymorphisms and colorectal cancer risk among Chinese in Singapore. Carcinogenesis. 2006;27:1797-802.
26. Meirhaeghe A, Fajas L, Helbecque N, et al. A genetic polymorphism of the peroxisome proliferator-activated receptor gamma gene influences plasma leptin levels in obese humans. Hum Mol Genet. 1998;7:435-440.
27. Jiang J, Gajalakshmi V, Wang J, et al. Influence of the C161T but not Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma on colorectal cancer in an Indian population. Cancer Sci. 2005;96:507-512.
28. Siezen CL, van Leeuwen AI, Kram NR, et al. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis. 2005;26:449-457.
29. Butt C, Gladman D, Rahman P. PPAR-gamma gene polymorphisms and psoriatic arthritis. J Rheumatol. 2006;33:1631-1633.
30. Szeto CC, Chow KM, Poon PY, et al. Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy. Am J Nephrol. 2008;28:715-722.
31. Wang XL, Oosterhof J, Duarte N. Peroxisome proliferator-activated receptor γ C161→T polymorphism and coronary artery disease. Cardiovasc Res. 1999;44:588-594.
32. Al-Shali KZ, House AA, Hanley AJG, et al. Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosis. Stroke. 2004;35:2036-2040.
33. Chao TH, Li YH, Chen JH, et al. The 161TT genotype in the exon 6 of the peroxisome-proliferator-activated receptor γ gene is associated with premature acute myocardial infarction and increased lipid peroxidation in habitual heavy smokers. Clin Sci (Lond). 2004;107:461-466.
34. Adachi M, Kurotani R, Morimura K, et al. Peroxisome proliferator activated receptor γ in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut. 2006;55:1104-1113.
35. Lewis JD, Lichtenstein GR, Stein RB, et al. An open-label trial of the PPAR gamma ligand rosiglitazone for active ulcerative colitis. Am J Gastroenterol. 2001;96:3323-3328.
36. Liang HL, Ouyang Q. A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis. World J Gastroenterol. 2008;14:114-119.
37. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis; a randomized placebo-controlled trial. Gastroenterology. 2008;134:688-695.
38. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med. 2005;201:1205-1215.
39. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology. 2003;124:1265-1276.
40. Sugawara K, Olson TS, Moskaluk CA, et al. Linkage to peroxisome proliferator-activated receptor-gamma in SAMP1/YitFc mice and in human Crohn's disease. Gastroenterology. 2005;128:351-360.
41. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 1989;170:2-6.
42. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19(Suppl A):5-36.
43. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
44. Gauderman WJ, Morrison JM. QUANTO 1.2: a computer program for power and sample size calculations for genetic-epidemiology studies; 2006. Available at: http://hydra.usc.edu/gxe.
45. Zhernakova A, Festen EM, Franke L, et al. Genetic analysis of innate immunity in Crohn's disease and ulcerative colitis identifies two susceptibility loci harboring CARD9 and IL18RAP. Am J Hum Genet. 2008;82:1202-1210.